| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| 200g |
|
||
| Other Sizes |
| Targets |
Beta-Cyclodextrin does not have a specific biological target. Its primary mechanism of action is based on its ability to form inclusion complexes with hydrophobic molecules. The hydrophobic cavity of beta-cyclodextrin can encapsulate guest molecules, improving their solubility, stability, and bioavailability. This property makes beta-cyclodextrin valuable as a drug delivery excipient and in various industrial applications.
|
|---|---|
| ln Vitro |
β-Cyclodextrin, also known as Beta-cyclodextrin or β-CD, is a cyclic polysaccharide that consists of seven glucose units (α-D-glucopyranose) connected by α-(1,4) type bonds. Its exterior is hydrophilic while its interior is hydrophobic[1]. β-Cyclodextrin (β-CD) is frequently utilized in the pharmaceutical industry to improve the solubility of medications, including citric acid, indomethacin, naringin, and celecoxib[2].
In vitro, beta-cyclodextrin is used as a complexing agent to improve the solubility, stability, and bioavailability of hydrophobic compounds. It is commonly used in pharmaceutical formulations as an excipient. Beta-cyclodextrin is also used in HPLC columns for chiral enantiomers separation. In cell-based assays, beta-cyclodextrin is used to deliver hydrophobic compounds to cells or to extract cholesterol from cell membranes. Its effects on cell viability are assessed using standard cytotoxicity assays. |
| ln Vivo |
In vivo, beta-cyclodextrin is used as a pharmaceutical excipient to improve the solubility and bioavailability of drugs. It is also used in food and cosmetic products. Beta-cyclodextrin is generally recognized as safe (GRAS) for use in food and pharmaceutical applications. It is not used as a therapeutic agent itself but as a delivery vehicle for other compounds. Comprehensive in vivo studies are available from regulatory assessments.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typically performed for beta-cyclodextrin, as it is an excipient rather than a pharmacologically active agent. Its ability to form inclusion complexes can be assessed using spectroscopic methods such as UV-Vis, fluorescence, or NMR spectroscopy. These assays confirm the compound's utility as a complexing agent.
|
| Cell Assay |
In vitro cell-based assays for beta-cyclodextrin evaluate its cytotoxicity and its ability to deliver hydrophobic compounds to cells. Cells are treated with beta-cyclodextrin alone or with beta-cyclodextrin-drug complexes, and cell viability is assessed using MTT or LDH release assays. The compound's ability to extract cholesterol from cell membranes is assessed by measuring cholesterol levels in cells. These assays confirm the compound's utility as a drug delivery excipient.
|
| Animal Protocol |
In vivo animal experiments for beta-cyclodextrin have been conducted in the context of toxicological and pharmacokinetic studies. Animals are administered beta-cyclodextrin, and its effects on drug absorption, distribution, metabolism, and excretion are assessed. The compound's safety profile has been evaluated in regulatory studies. Beta-cyclodextrin is generally recognized as safe (GRAS) for use in food and pharmaceutical applications.
|
| ADME/Pharmacokinetics |
Beta-cyclodextrin is not absorbed systemically to a significant extent after oral administration. It is metabolized by colonic microflora and excreted in feces. The compound has a molecular weight of 1134.99 g/mol. It is a solid powder. Beta-cyclodextrin is generally recognized as safe (GRAS) for use in food and pharmaceutical applications.
|
| Toxicity/Toxicokinetics |
The toxicity of beta-cyclodextrin is low. It is generally recognized as safe (GRAS) for use in food and pharmaceutical applications. High doses may cause gastrointestinal disturbances. Beta-cyclodextrin is used as a pharmaceutical excipient and food additive. It is not intended for use as a therapeutic agent.
|
| References |
|
| Additional Infomation |
β-Cyclodextrin is a cyclodextrin composed of seven α-(1→4) linked D-pyranose units. Romanoa has been reported to contain β-cyclodextrin, and relevant data are available. See also: Caraway (note moved to).
Beta-Cyclodextrin is a cyclic oligosaccharide composed of seven glucose units joined by α-1,4 bonds. It has a molecular formula of C₄₂H₇₀O₃₅ and a molecular weight of 1134.99 g/mol. Beta-Cyclodextrin is used in HPLC columns for chiral separation, as a drug delivery excipient, and in food, medicine, and cosmetics. It is generally recognized as safe (GRAS). |
| Molecular Formula |
C42H70O35
|
|---|---|
| Molecular Weight |
1134.9842
|
| Exact Mass |
1134.369
|
| Elemental Analysis |
C, 44.45; H, 6.22; O, 49.34
|
| CAS # |
7585-39-9
|
| Related CAS # |
79647-56-6
|
| PubChem CID |
444041
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
1541.2±60.0 °C at 760 mmHg
|
| Melting Point |
>260ºC (dec.)(lit.)
|
| Flash Point |
885.9±32.9 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.591
|
| LogP |
-6.57
|
| Hydrogen Bond Donor Count |
21
|
| Hydrogen Bond Acceptor Count |
35
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
77
|
| Complexity |
1480
|
| Defined Atom Stereocenter Count |
35
|
| SMILES |
O1[C@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O2)O[C@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O2)O[C@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O2)O[C@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O2)O[C@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O2)O[C@]2([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O2)O[C@]2([H])[C@@]([H])([C@]([H])([C@@]1([H])[C@@]([H])(C([H])([H])O[H])O2)O[H])O[H])O[H])O[H])O[H])O[H])O[H])O[H])O[H])O[H])O[H])O[H])O[H])O[H]
|
| InChi Key |
WHGYBXFWUBPSRW-UOFYCTJFSA-N
|
| InChi Code |
InChI=1S/C42H70O35/c43-1-8-29-15(50)22(57)36(64-8)72-30-9(2-44)66-38(24(59)17(30)52)74-32-11(4-46)68-40(26(61)19(32)54)76-34-13(6-48)70-42(28(63)21(34)56)77-35-14(7-49)69-41(27(62)20(35)55)75-33-12(5-47)67-39(25(60)18(33)53)73-31-10(3-45)65-37(71-29)23(58)16(31)51/h8-63H,1-7H2/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-/m1/s1
|
| Chemical Name |
(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol
|
| Synonyms |
β-Cyclodextrin, beta-Cyclodextrin; BCD; Betadex; CCRIS651; CCRIS-651; CCRIS 651
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~38.75 mg/mL (~34.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8811 mL | 4.4054 mL | 8.8107 mL | |
| 5 mM | 0.1762 mL | 0.8811 mL | 1.7621 mL | |
| 10 mM | 0.0881 mL | 0.4405 mL | 0.8811 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
